A phase 1b/2a multicenter study of the safety and preliminary pharmacodynamic effects of selective muscarinic M 1 receptor agonist HTL0018318 in patients with mild-to-moderate Alzheimer's disease.

Pradeep J Nathan,S Babli Millais, Alex Godwood,Odile Dewit,David M Cross, Janet Liptrot, Bharat Ruparelia, Stephen Paul Jones,Geor Bakker,Paul T Maruff,Gregory A Light,Alastair J H Brown, Malcolm Peter Weir,Miles Congreve,Tim Tasker

Alzheimer's & dementia (New York, N. Y.)（2022）

引用 4|浏览11

暂无评分

摘要

HTL0018318 was well tolerated in mild-to-moderate AD patients and showed positive effects on attention and episodic memory on top of therapeutic doses of donepezil.

查看译文

关键词

Alzheimer's disease,Cogstate neuropsychological test battery,HTL0018318,attention,cholinergic,clinical trial,cognition,electrophysiology,event related potential,memory,muscarinic M1 receptor,pharmacodynamic,safety,symptomatic,tolerability

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要